Colesevelam hydrochloride: a novel bile acid-binding resin

• Published in: The Annals of pharmacotherapy 2001-07, Vol.35 (7), p.898-907
• Main Authors: Aldridge, MA, Ito, MK
• Format: Article
• Language: English
• Subjects: Adult; Aged; Allylamine - adverse effects; Allylamine - analogs & derivatives; Allylamine - pharmacokinetics; Allylamine - therapeutic use; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - pharmacokinetics; Anticholesteremic Agents - therapeutic use; Biological and medical sciences; Biological Availability; Carrier Proteins - pharmacology; Cholesterol, LDL - blood; Colesevelam Hydrochloride; Drug Interactions; Female; General and cellular metabolism. Vitamins; Humans; Hydroxysteroid Dehydrogenases; Hypercholesterolemia - drug therapy; Male; Medical sciences; Membrane Glycoproteins; Middle Aged; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic
• ISSN: 1060-0280; 1542-6270
• DOI: 10.1345/aph.10263

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of colesevelam hydrochloride, a bile acid—binding resin. METHODS: MEDLINE searches (1966–June 2000) and manufacturer prescribing literature were employed to find articles on colesevelam. Additional studies and abstracts were identified from the bibliographies of reviewed literature. STUDY SELECTION AND DATA EXTRACTION: All articles identified from data sources were evaluated, and all information deemed relevant was included in this review. Priority was given to randomized, double-blind, placebo-controlled studies. FINDINGS: Colesevelam HCl is a nonabsorbed hydrogel with bile acid sequestrant properties. Monotherapy using colesevelam in once-daily or two divided daily doses of 1.5–4.5 g has produced significant reductions in total cholesterol and low-density lipoprotein (LDL) cholesterol. Mean LDL cholesterol decreases to 20% have been noted when the patient is on 3.75–4.5 g/d. Increases in high-density lipoprotein (HDL) cholesterol have been observed (up to 9%), whereas triglycerides (TG) have increased significantly to 25% in some studies. In unpublished studies, combined use of colesevelam plus hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor have produced greater reductions in LDL cholesterol than either the statin or colesevelam administered alone. The efficacy of colesevelam monotherapy is slightly less than or similar to cholestyramine or colestipol in decreasing LDL cholesterol, although colesevelam is more potent on a gram-to-gram basis. Adverse effects have been minimal with colesevelam in published studies; this suggests an advantage over cholestyramine or colestipol therapy. Colesevelam appears to be more cost-effective than the packet dosage form of the brand formulation of the older bile acid resins. Care in selection of an appropriate agent should be exercised when considering the issues of adverse effects and palatability. CONCLUSIONS: Colesevelam alone or combined with an HMG-CoA reductase inhibitor is effective in the reduction of total and LDL cholesterol. Since colesevelam is formulated as a tablet, problems with palatability such as with the powder formulation of the bile acid—binding resins are likely to be eliminated.